Cardiff Oncology Inc. Common Stock (CRDF)

FairStock Score: 57/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for a durable business with owner earnings and a margin of safety. Cardiff Oncology offers neither today. It is a clinical-stage biotech with 30 employees and a lead drug, Onvansertib, still in trials. In fiscal 2025, the year ended 2025-12-31, revenue was just $593,000 and net loss was $45.9 million, or $0.69 per diluted share. In fiscal 2024, the year ended 2024-12-31, revenue was $683,000 and net loss was $45.4 million. So the top line is tiny and declining, while losses remain enormous. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, showed revenue of $104,000 and a net loss of $9.2 million. Trailing free cash flow is negative $40.9 million, a -52.1% FCF yield on the $78.6 million market cap at the 2026-10-13 close. That is a cash incinerator, not a compounding machine. The balance sheet shows low leverage—D/E 0.02—which helps, but Altman Z-score -12.62 signals financial distress and Piotroski 4/9 confirms weak fundamentals. FairStock calculations based on the 2026-10-13 close show P/B 2.59 and P/E -1.68; ROE is -94.08% and ROCE is -46.73%. Without profits, book value is not a reliable floor. The Lynch category is none because it has lost money in each of the last four years. The only real asset is the pipeline, and its value is binary and unknowable until clinical data mature. I need evidence of a moat, pricing power, and consistent cash generation. Here, I see a speculative research project with a high chance of dilution or failure. Price may be low, but value is not the same as a low price.

In plain English: Cardiff Oncology is a small clinical-stage biotech developing a cancer drug, mainly for colorectal cancer. It has almost no revenue and loses millions of dollars each quarter, so the business looks weak today. At $1.01, the price does not look cheap compared with those numbers; the value depends almost entirely on future drug trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer